Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis and Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and Large Patient Populations
Amount Raised
$95 Million
Round Type
Series B
DallasBiotechnologyDescription
Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, today announced that it has closed an oversubscribed $95 million Series B financing with a premier syndicate of life science investors, led by Fidelity Management & Research Company LLC. Additional new investors include funds and accounts managed by BlackRock, GV (formerly Google Ventures), Invus, Casdin Capital, Franklin Templeton, Octagon Capital, Perceptive Advisors LLC, Sands Capital, ArrowMark Partners and Venrock Healthcare Capital Partners. Also participating in the round were founding investors PBM Capital and Nolan Capital. Proceeds from the Series B financing will be used to advance the initial cohort of lead programs into the clinic, accelerate progress on anticipated IND submissions, build a commercially scalable GMP manufacturing facility and continue development of the company’s extensive portfolio of potentially curative gene therapies in partnership with the UT Southwestern Gene Therapy Program.
Quick answer
Taysha Gene Therapies, Inc. raised $95 Million in a Series B round, dated August 5, 2020. Taysha Gene Therapies, Inc. is based in Dallas, Texas, United States.
- How much did Taysha Gene Therapies, Inc. raise?
- Taysha Gene Therapies, Inc. raised $95 Million in a Series B round on August 5, 2020.
- What does Taysha Gene Therapies, Inc. do?
- Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease.
- Where is Taysha Gene Therapies, Inc. based and how big is it?
- Taysha Gene Therapies, Inc. is based in Dallas, Texas, United States.
- Who are the decision-makers at Taysha Gene Therapies, Inc?
- Fundz holds 1 contact at Taysha Gene Therapies, Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Taysha Gene Therapies, Inc. that raised within 45 days of this round, from Fundz verified event records.
- Silicon Valley Innovations, Inc. raised $2.6M (Seed) on September 18, 2020.
- Lassogen, Inc. raised $5.1M on September 18, 2020.
- Finch Therapeutics Group, Inc. raised $88M on September 17, 2020.
- LAVA Therapeutics raised $83M (Series C) on September 17, 2020.
- AgroSpheres raised $485K (Seed) on September 17, 2020.
- BioNTech raised $250M on September 17, 2020.
Who to call at Taysha Gene Therapies, Inc., and when
A new round usually means Taysha Gene Therapies, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Taysha Gene Therapies, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Taysha Gene Therapies, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Taysha Gene Therapies, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Taysha Gene Therapies, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTaysha Gene Therapies, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.